Cardiff Oncology
CRDF
29 hedge funds and large institutions have $1.21M invested in Cardiff Oncology in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 14 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
29% more capital invested
Capital invested by funds: $936K → $1.21M (+$272K)
5.22% more ownership
Funds ownership: 0.07% → 5.29% (+5.2%)
22% less funds holding
Funds holding: 37 → 29 (-8)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.09M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$857K |
| 3 |
Renaissance Technologies
New York
|
+$538K |
| 4 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$181K |
| 5 |
SNB
Security National Bank
Omaha,
Nebraska
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$119K |
| 2 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$44K |
| 3 |
VF
Virtu Financial
New York
|
-$37K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$27K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$20K |
CRDF Hedge Fund Activity: Q2 2018 in Review
29 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2018, worth a combined $1.21M — up 29% from $936K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CRDF and 7 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 9 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.09M. The largest seller was Vanguard Group, cutting an estimated $119K.
- 29 institutional investors held Cardiff Oncology (CRDF) as of Q2 2018, down from 37 in Q1 2018.
- Funds reported $1.21M of Cardiff Oncology stock for Q2 2018, up 29% quarter-over-quarter.
- 7 funds opened new Cardiff Oncology positions in Q2 2018 and 14 closed out, a net change of -7 holders.
- The largest Cardiff Oncology buyer in Q2 2018 was Sabby Management, an estimated $2.09M added.
- The largest Cardiff Oncology seller in Q2 2018 was Vanguard Group, an estimated $119K sold.
Based on aggregated 13F filings for Q2 2018.